Lexicon Pharmaceuticals (LXRX) Accumulated Expenses (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Accumulated Expenses data on file, last reported at $6.9 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $6.9 million, down 46.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 million (down 46.69% YoY), and the FY2025 annual result was $13.2 million, down 56.68% from the prior year.
• Accumulated Expenses fell to $6.9 million in Q1 2026 per LXRX's latest filing, from $13.2 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $30.4 million in Q4 2024 and troughed at $6.9 million in Q1 2026.
• A 5-year average of $14.4 million and a median of $13.2 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses sank 57.23% in 2022, then surged 124.27% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $12.8 million in 2022, then jumped by 34.28% to $17.2 million in 2023, then surged by 77.46% to $30.4 million in 2024, then sank by 56.68% to $13.2 million in 2025, then slumped by 47.67% to $6.9 million in 2026.
• Business Quant data shows LXRX's Accumulated Expenses at $6.9 million in Q1 2026, $13.2 million in Q4 2025, and $13.6 million in Q3 2025.